Navigation Links
Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
Date:9/29/2008

First complement inhibitor to be tested in AMD patients

LOUISVILLE, Ky., Sept. 29 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD) announced today that the Company's leading drug candidate, POT-4, has shown early positive safety results in its Phase I study. POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF). Based on this mechanism of action, POT-4 holds the potential to be effective against both dry and wet AMD.

"POT-4 has generated encouraging safety and tolerability data in this Phase I study and holds significant promise as a novel agent for treating AMD; a debilitating condition for which there is no cure," said Cedric Francois, President and CEO of Potentia. "As a result of the favorable early data, it was decided to expand the trial to permit further dose escalation, with the goal of prolonging the pharmacological benefit from POT-4. Potentia looks forward to the presentation of the Phase I data at a future medical conference and, with additional information gained from the extension of the study, to the initiation of Phase II trials in the future."

About AMD

AMD is the leading cause of blindness in the elderly of the western world and affects more than 10 million patients in the United States alone. The current standard of care for AMD relies primarily on angiogenesis inhibitors, an approach geared towards the approximately 10-15% of AMD patients with complications resulting from ocular angiogenesis (growth of new blood vessels and bleeding in the back of the eye). No drug currently on the market has been approved for the treatment of the remaining patients, who suffer from the so-called "dry" form of the disease.

Abo
'/>"/>

SOURCE Potentia Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
4. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
5. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
6. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
7. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
8. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
9. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
10. Potential Early Warning System for Lung Cancer Identified
11. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a late-stage ... Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical ... investor conferences in September. , ... LLC Emerging Growth Conference in New ... President & Chief Executive Officer, will present a corporate ...
(Date:8/31/2015)... , August 31, 2015 ... BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, today announced ... MCTC), has identified several new genetic markers with ... in patients treated with bisphosphonate drugs and was ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... dosed at Chicago -based Rush ... trial evaluating activity of escalating doses of AST-OPC1 ... sensory and motor complete cervical spinal cord injury ...
Breaking Medicine Technology:Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... Calif., Oct. 7 Onyx Pharmaceuticals, Inc. (Nasdaq: ... its New Drug Application (NDA) filing for carfilzomib based ... Controls (CMC) review division of the U.S. Food and ... information related to commercial-scale manufacturing of carfilzomib.  Onyx had ...
... NEW YORK, Oct. 7 Reportlinker.com announces that a ... European RIS/PACS Market ... European RIS/PACS market in terms of the challenges faced ... The main chapters of the research service include an ...
Cached Medicine Technology:Onyx Pharmaceuticals Provides Status Update on Carfilzomib 2Onyx Pharmaceuticals Provides Status Update on Carfilzomib 3Reportlinker Adds European RIS/PACS Market 2Reportlinker Adds European RIS/PACS Market 3
(Date:8/31/2015)... Santa Rosa Beach, FL (PRWEB) , ... August 31, 2015 , ... ... Southern family of companies – has teamed up with fellow South Walton property ... organization focused on eliminating extreme poverty in remote parts of the world. The two ...
(Date:8/31/2015)... ... August 31, 2015 , ... Wound Care Advantage, ... company’s second Introduction to Hyperbaric Medicine Course. The next UHMS approved 40-hour Introduction ... Mary Hotel in Long Beach, CA. The meeting is open for registration from ...
(Date:8/31/2015)... ... August 31, 2015 , ... Women’s Excellence in ... , Starting September 1st they are offering pre and postnatal fitness classes on ... Healthy Baby." , More information can be found at 248-601-6683. , Women’s Excellence ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... The ... healthcare to Veterans residing across southwest Florida by hiring more doctors and nurses and ... list of expanded services. , In early July, Dr. Anthony Jabre was selected to ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... formed in 2008, the result of a merger of five of the busiest ... cooperatively, they could provide more cost-effective and higher quality care than they did ...
Breaking Medicine News(10 mins):Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:NJ Top Docs Presents, Garden State Urology! 2
... a platinum-based anticancer drug that,s made enormous headway in ... damage that may be permanent and worsens even months ... Johns Hopkins researchers in the September issue of ... be the first effort to track oxaliplatin-based nerve damage ...
... Serena Gordon HealthDay Reporter , TUESDAY, Sept. 27 ... screening earlier than women, new research suggests. The study ... precancerous lesions (also called polyps or adenomas) in their colon ... women -- and to have them at an earlier age. ...
... habits of a romantic partner,s friends are more likely to ... an adolescent,s own friends or significant other, according to a ... Review. "Dating someone whose friends are big drinkers is ... drinking behaviors than are the drinking habits of the adolescent,s ...
... on aging are headed for meetings with their senators ... senior population, spurred by the first-ever Take Action Week ... nation,s largest interdisciplinary organization devoted to the field of ... period, these advocates will urge their elected leaders to ...
... JOLLA, CA -- September 27, 2011 -- Scripps Research ... $3.6 million MERIT (Method to Extend Research in Time) ... to study the risk factors for alcoholism in Native ... to better understand alcohol dependence and alcohol-related problems in ...
... Reporter , TUESDAY, Sept. 27 (HealthDay News) -- Many ... when the going gets slow, fiber seems to beat ... suggests. A review of nine studies with 640 ... has no known physical cause, found that fiber supplements ...
Cached Medicine News:Health News:Popular colorectal cancer drug may cause permanent nerve damage 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 3Health News:Adolescents particularly susceptible to drinking habits of romantic partner's friends 2Health News:Congress must protect funds for aging America, advocates say 2Health News:Scripps research scientist wins $3.6 million NIH Method to Extend Research in Time award to study alcoholism in Native Americans 2Health News:Fiber Beats Other Remedies for Constipated Kids, Study Says 2Health News:Fiber Beats Other Remedies for Constipated Kids, Study Says 3
... is an Anterior Cervical Plating System ... flexibility and simplicity for the spinal ... function and safe fixation of the ... meet the needs of the spinal ...
... cervical spinal compression plate acc. to Matzen ... the cervical spine (HWS) with the exception ... immobilization of the fusion length until the ... fixed anteriorly on the vertebral bodies, if ...
The Codman anterior cervical plate is designed for immediate internal fixation of the cervical spine following bone grafting procedures....
... small things. The extremely small,HiLAN XS ... trailblazers of the new,generation of miniaturized ... smaller access and the demand for ... HiLAN XS motor concept is the ...
Medicine Products: